| Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia. | |
| | |
MedLine Citation:
|
PMID: 3478535 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The validity of an in vitro clonogenic drug sensitivity assay to predict the induction and the duration of complete remission was evaluated in a group of 81 patients with acute myelogenous leukemia treated with chemotherapy including an anthracycline drug (daunorubicin or adriamycin) and cytosine arabinoside (Ara-C). The inhibition of bone marrow clonogenic leukemic cells by in vitro exposure to anthracyclines 10(-5) and 10(-6) M, Ara-C 10(-5) M, and daunorubicin 10(-6) M + Ara-C 10(-7) M was significantly correlated with the achievement of a complete remission, but not with the duration of remission. A high second plating efficiency was correlated with short duration of complete remission, reflecting the poor prognosis of a high self-renewal capacity. |
| | |
Authors:
|
J P Marie; R Zittoun; A Delmer; D Thevenin; A M Suberville |
Related Documents
:
|
12877645 - Acute promyelocytic leukaemia:a review. 15842665 - One versus two high-dose cytarabine-based consolidation before autologous stem cell tra... 12243555 - Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabino... 113075 - Treatment of acute leukemia in protected environment units. 6295615 - Chemotherapy of malignant fibrous histiocytoma of bone. a report of five cases. 14652675 - Effects of radiation treatment planning and patient fixation on the results of postoper... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Leukemia Volume: 1 ISSN: 0887-6924 ISO Abbreviation: Leukemia Publication Date: 1987 Feb |
Date Detail:
|
Created Date: 1987-12-07 Completed Date: 1987-12-07 Revised Date: 2013-03-04 |
Medline Journal Info:
|
Nlm Unique ID: 8704895 Medline TA: Leukemia Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 121-6 Citation Subset: IM |
Affiliation:
|
Laboratoire de Cinétique et de Culture Cellulaire, Hôtel-Dieu de Paris, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Agents / therapeutic use* Colony-Forming Units Assay Cytarabine / administration & dosage Daunorubicin / administration & dosage Dose-Response Relationship, Drug Female Humans Leukemia, Myeloid, Acute / drug therapy, pathology* Male Middle Aged Prognosis Time Factors Tumor Cells, Cultured / drug effects, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 147-94-4/Cytarabine; 20830-81-3/Daunorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.
Next Document: Prognostic implication of hyperdiploidy as based on DNA flow cytometric measurement in childhood acu...